Arvinas (ARVN) Insider Briggs Morrison Buys 22,714 Shares

Briggs Morrison, an insider at Arvinas, Inc., purchased 15,527 shares of the company on June 24, 2026. This transaction was not part of a pre-planned trading program, indicating Morrison's active decision to increase his stake in the biotech firm.

Insider Buying and Selling at Arvinas, Inc.

On June 24, 2026, several insiders, including Briggs Morrison, were active in buying shares of Arvinas, Inc. Linda Bain purchased 22,714 shares, Edward Moore Jr. and Laurie Smaldone Alsup each acquired 15,527 shares, and Leslie Norwalk also bought 15,527 shares. These transactions were not planned under Rule 10b5-1, suggesting a concerted effort by the insiders to strengthen their positions.

Arvinas, Inc. Stock Down 3.5%

Shares of NasdaqGS:ARVN traded near $8.03 on Saturday. Arvinas, Inc. has a market capitalization of approximately $518.1 million. The company is not currently profitable, with a forward P/E ratio indicating losses. The stock has seen a 52-week low of $6.06 and a high of $14.51. Its 50-day moving average is $9.08, while the 200-day moving average is $10.67. Arvinas maintains a strong liquidity position, with a current ratio of 5.44 and a quick ratio of 5.36.

Analysts Set New Price Targets

Analysts remain optimistic about Arvinas, Inc. On June 3, 2026, Stephens & Co. reiterated a buy rating with an $18 price target. Similarly, Barclays and BTIG maintained buy ratings with targets of $20 and $18, respectively, earlier in May. Citigroup has been particularly bullish, maintaining a buy rating with a top target of $24. Overall, the consensus recommendation is a buy, with the average target price set at $14.80 among 15 analysts.

About Arvinas, Inc.

Arvinas, Inc. is a biotechnology company based in New Haven, Connecticut, specializing in the development of therapies that degrade disease-causing proteins. The company is known for its innovative PROTAC technology, which utilizes the body's natural protein disposal system. Arvinas is actively developing treatments for neurodegenerative diseases and various cancers, working in collaboration with major pharmaceutical companies like Pfizer and Genentech. Led by CEO Dr. Randy Teel, the company employs 246 people.

Bottom Line

Briggs Morrison's recent purchase of Arvinas, Inc. shares highlights insider confidence in the company's prospects. Investors often track such insider activities as potential indicators of a company's future performance. However, it's important to remember that these transactions are historical and may not reflect current positions. Arvinas continues to attract analyst attention with optimistic price targets, suggesting a positive outlook from the market.